Evidence map›Paper›PMID 41862682›Full record

ArticleActa pharmacologica Sinica2026

Hippocampal REDD1 inhibition is critical for alleviating depressive-like behaviors.

Chen Xu, Meng-Xing Liao, Shi-Ze Zhang, Lai-Xin-Yue Shu, Peng Xu, Yu-Ang Chen, Meng-Qin Wang, Tian Cheng, Xu-le Yang, Yuan Xie and 2 more

Abstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chen XuJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Meng-Xing LiaoJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Shi-Ze ZhangJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Lai-Xin-Yue ShuJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Peng XuKey Laboratory of Drug Monitoring and Control, Drug Intelligence and Forensic Center, Ministry of Public Security, Beijing, 100193, China.
Yu-Ang ChenJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Meng-Qin WangJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Tian ChengJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Xu-le YangJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
Yuan XieJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. yuanxie@cpu.edu.cn.
Guang-Ji WangJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. guangjiwang@hotmail.com.
Ji-Ye AaJiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China. jiyea@cpu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression is characterized by distinct pathological and synaptic abnormalities in the hippocampus; however, the underlying mechanisms remain poorly understood. We demonstrate for the first time that Regulated in development and DNA damage response-1 (REDD1) is upregulated in hippocampal neurons in three depression models induced by typical stressors. Notably, the hippocampus is the only brain region where REDD1 is highly expressed-this effect is not observed in the hypothalamus, prefrontal cortex, nucleus accumbens, or dorsal raphe. Downregulation of REDD1 effectively rescued depressive-like behaviors in chronic social defeat stress (CSDS) model mice, activated mTORC1 in hippocampal neurons, and reduced synaptic loss, while overexpression of REDD1 specifically in hippocampal neurons triggered depressive-like behaviors in non-stressed mice. These findings were further validated using REDD1 knockdown and mTORC1 inhibition models. Moreover, a novel compound, X837, potently inhibited REDD1, leading to rapid alleviation of depression-like behaviors, robust activation of the mTORC1 pathway, and restoration of synaptic deficits. The antidepressant effects of X837 were dependent on the REDD1/mTORC1 axis in hippocampal neurons. In conclusion, REDD1 in hippocampal neurons is a potent antidepressant target which functions via the mTORC1 signaling pathway. Interfering with REDD1 is a potential target to rescue depressive-like behaviors.

Indexed as

Antidepressive AgentsDepressionHippocampusTranscription FactorsAdaptor Proteins, Signal TransducingAnimalsBehavior, AnimalMaleMechanistic Target of Rapamycin Complex 1MiceMice, Inbred C57BLNeuronsAdaptor Proteins, Signal TransducingAntidepressive AgentsDdit4l protein, mouseDdit4 protein, mouseMechanistic Target of Rapamycin Complex 1Transcription FactorsdepressionhippocampusmTORC1REDD1synaptic protein

Identifiers

PMID41862682
PMCPMC13280374

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.